We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Diagnostic Device Profiles Population of Gut Microbiome

By LabMedica International staff writers
Posted on 05 Aug 2019
Researchers used a three-dimensional (3D) printer to manufacture a novel pill-like diagnostic tool capable of profiling the bacterial species comprising the gut microbiome in the critical area between the stomach and the colon.

Investigators at Tufts University (Medford/Somerville, MA, USA) recently described a novel non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract. More...
The device was manufactured in a three-dimensional printer.

The surface of the pill was covered with a pH-sensitive coating, so that it did not absorb any substances until it passed through the stomach and entered the small intestine, where the coating dissolved. A semi-permeable membrane separated two chambers in the pill - one containing helical channels that captured bacteria and the other containing a calcium salt-filled chamber, which created an osmotic flow across the membrane that forced the bacteria into the helical channels. A small magnet in the pill enabled controlled movement and targeting via a magnet outside the body. Finally, a fluorescent dye in the salt chamber marked the pill for easy identification after it left the body.

The pill's sampling performance was characterized using realistic in vitro models and validated in vivo in pigs and primates. So far, results have indicated that the bacterial populations recovered from the pills’ microfluidic channels closely resembled the bacterial population demographics of the microenvironment to which the pill was exposed. Despite these promising results, clinical trials will be needed to determine if the pill can be adapted for routine use in humans.

"We are learning quite a lot about the role of gut microbiome in health and disease. However, we know very little about its biogeography," said senior author Dr. Sameer Sonkusale, professor of electrical and computer engineering at Tufts University. "The pill will improve our understanding of the role of spatial distribution in the microbiome profile to advance novel treatments and therapies for a number of diseases and conditions."

The microbiome profiler was described in the July 19, 2019, online edition of the journal Advanced Intelligent Systems.

Related Links:
Tufts University


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.